Search
for
Sort by
Research 91–120 of 774
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Alopecia universalis successfully treated with tofacitinib
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Janus kinase inhibitors for alopecia areata: A narrative review
- Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
- Current and future pharmacotherapy for alopecia areata
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Efficacy of tofacitinib in pediatric alopecia universalis
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Baricitinib: A Review in Severe Alopecia Areata
- Janus Kinase inhibitors in dermatology: a review
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- The role of janus kinases in the treatment of autoimmune skin diseases
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata